AnalystBook Research · Company Intelligence

AMARIN CORP PLCUK

AMRNNasdaq

Built from AMARIN CORP PLCUK's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Amarin revenue fell 6.5% to $213.6M, the net loss narrowed to $38.8M, and free cash flow improved to $6.7M.

The read at a glance✓ Audited against SEC data
  • Business mix — Cardiovascular drug commercializationNote
  • Revenue — Revenue fell 6.5% to $213.6MWatch
  • Profitability — Net loss narrowed 52.8%Note
  • Cash — Free cash flow improved to $6.7MOK
  • Balance sheet — Equity fell 5.5%Watch
  • Insiders — 0 buys / 0 sellsNote
  • Accounting — Altman-Z distress; EQ safeWatch

Business

Amarin focuses on cardiovascular therapeutics, with VASCEPA as the main commercial product and licensing relationships contributing to revenue.

Where the revenue comes from

Fiscal 2025, as AMARIN CORP PLCUK reports it. History and quarterly detail are in the app.

  • Product$182.8M
  • License$40.1M
  • Licensing And Royalty$30.9M
  • Royalty$2.5M

Leadership changes

From AMARIN CORP PLCUK's own filings, the day they're filed.

  • David Keenan · President · appointmenteff. 2025-10-17
  • Michael Torok · Directors · appointmenteff. 2025-04-04
  • Peter Fishman · Chief Financial Officer · appointmenteff. 2024-12-13

Latest filings

  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-05-15
  • 10-Q · Quarterly report2026-04-29
  • 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AMARIN CORP PLCUK, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full AMRN record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.